FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed is application of CCR5 antagonist maraviroc or its pharmaceutically acceptable salt (solvate) for increasing number of cells CD4, or CD8, or both CD4, and CD8 in HIV-infected patient, as well as application of maraviroc for increasing number of cells CD4, or CD8, or both CD4 and CD8 in patient with HIV, infected by virus population, using CXCR4. It is demonstrated that maraviroc in addition to earlier known inhibition of HIV penetration in patients, enhanced immunorestorative therapy in treatment of HIV-associated opportunistic patient/s states with impaired immune status.
EFFECT: invention also makes it possible to treat with CCR5 antagonist maraviroc of patients, which has virus population, using CXCR4, as for such patients increase of their CD4 and/or CD8cells will be also useful.
13 cl, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CCR5 EXPRESSION SUPRESSION COMPOSITIONS AND METHODS OF APPLICATION THEREOF | 2004 |
|
RU2353357C2 |
| DOUBLE VECTOR FOR SUPPRESSION OF HUMAN IMMUNODEFICIENCY VIRUS | 2010 |
|
RU2562868C2 |
| ANTI-CXCR4 ANTIBODIES FOR TREATMENT OF HIV INFECTION | 2010 |
|
RU2573902C2 |
| COMPOSITIONS AND METHODS FOR APPLYING PHORBOL ESTERS | 2008 |
|
RU2472511C2 |
| METHOD AND COMPOSITION FOR PREVENTING HIV INFECTION, PREVENTING AND TREATING HIV-CAUSED OR HIV-ASSOCIATED DISEASES, INCLUDING AIDS | 2010 |
|
RU2516931C2 |
| QUINOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING VIRAL INFECTION | 2016 |
|
RU2723016C2 |
| HIV-INFECTION TREATMENT BY T-CELL MODULATION | 2005 |
|
RU2393872C2 |
| ANTIBODY AND CHEMOKINE CONSTRUCTS AND USES THEREOF IN IMMUNOLOGICAL DISORDERS | 2001 |
|
RU2252786C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIRETROVIRAL DRUG AND PHARMACOKINETICS IMPROVER | 2017 |
|
RU2745204C2 |
| USING COX-2 INHIBITORS FOR PROPHYLAXIS OF IMMUNODEFICIENCY | 2001 |
|
RU2303452C2 |
